Abstract
Introduction:
The objective of our study was to identify the clinicopathologic factors that are associated with increased risk of recurrence in borderline ovarian tumors (BOTs).
Materials and Methods:
We performed a retrospective review of 75 cases of BOT treated at our institute from January 2004 to December 2018. Disease-free survival (DFS) was calculated from the date of surgery to the date of recurrence or last follow-up. Overall survival was calculated from the date of surgery to date of death or last follow-up. Univariate analyses with log-rank tests and multivariate Cox regression models with backward variable selection procedures were used to explore the impact of various clinicopathologic factors on DFS.
Results:
The median age of patients was 42 years. Complete staging was done in 47 patients. Sixty-four patients had FIGO (International Federation of Obstetrics and Gynecology) stage I, five had stage II, and six had stage III disease. Twenty-seven patients underwent fertility-sparing surgery. Implants were seen in 11 patients, with invasive implants in 6 patients. Seven patients received adjuvant chemotherapy. Seven patients developed borderline recurrence and five developed invasive recurrence over a median follow-up of 53 months. All the patients with borderline relapses were successfully managed by second surgery. Three patients with invasive recurrence died of disease. On multivariate analysis, only incomplete staging (p = 0.009) and advanced stage (p = 0.002) were associated with worse DFS.
Conclusion:
Advanced-stage disease and incomplete staging are associated with increased risk of recurrence in BOTs. (J GYNECOL SURG 37:214)
Get full access to this article
View all access options for this article.